Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.68 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.48 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.48 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.48 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
| ▸ | KMO | O15229 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | CLK2 | P49760 | 1/20 | 0.46 |
| ▸ | CDK7 | P50613 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL529524 | 0.89 | MGAM (0.57) | MGAMPDGFRBPDGFRAMAP4K4CLK4 | |
| SCHEMBL12504970 | 0.88 | MGAM (0.56) | MGAMMAP4K4CLK4CSNK1G2MKNK2 | |
| SCHEMBL529465 | 0.88 | MAP4K4 (0.63) | MGAMPDGFRBPDGFRAMAP4K4CLK4 | |
| SCHEMBL4123055 | 0.87 | MGAM (0.58) | MGAMPDGFRBPDGFRAMAP4K4CLK4 | |
| SCHEMBL27970954 | 0.83 | RXRA (0.62) | MGAMPDGFRBPDGFRAMAP4K4CLK4 | |
| SCHEMBL10465639 | 0.83 | MGAM (0.70) | MGAMPDGFRBPDGFRAKDM4ESMN1; SMN2 | |
| SCHEMBL15774917 | 0.81 | KDM4E (0.64) | MGAMKDM4ESMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL28048 | 0.81 | MGAM (1.00) | MGAMPDGFRBPDGFRAMAP4K4CLK4 | |
| SCHEMBL29362407 | 0.81 | MGAM (1.00) | MGAMPDGFRBPDGFRAMAP4K4CLK4 | |
| SCHEMBL8889438 | 0.80 | PDGFRB (0.55) | PDGFRBPDGFRAMAP4K4CLK4CSNK1G2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103906735-A | Novel aryl-quinoline derivatives | HOFFMANN LA ROCHE | 2014-07-02 | — | — | CN | disclosed |
| CN-1740169-B | Arylmethylamine derivatives for use as tryptase inhibitors | AVENTIS PHARMA INC | 2010-04-21 | — | — | CN | disclosed |
| EP-1296972-B1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMA INC (US) | 2009-12-23 | — | — | EP | disclosed |
| CN-1740169-A | Arylmethylamine derivatives for use as tryptase inhibitors | AVENTIS PHARMA INC (US) | 2006-03-01 | — | — | CN | disclosed |
| US-6977263-B2 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-20 | — | — | US | disclosed |
| CN-1230431-C | Arylmethylamine derivatives useful as tryptase inhibitors | AVENTIS PHARM PROD INC (US) | 2005-12-07 | — | — | CN | disclosed |
| US-20050228018-A1 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-13 | — | — | US | disclosed |
| US-20030187020-A1 | Chemical compounds | AVENTISUB LLC | 2003-10-02 | — | — | US | disclosed |
| CN-1439003-A | Arylmethylamine derivatives useful as tryptase inhibitors | AVENTIS PHARM PROD INC (US) | 2003-08-27 | — | — | CN | disclosed |
| EP-1296972-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001090101-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228018-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | MGAM 369/4885PDGFRB 607/4885PDGFRA 683/4885 |
| US-20030187020-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | MGAM 369/4885PDGFRB 607/4885PDGFRA 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.